One Genomics Partners with CiRA Foundation to Advance High-Precision CRISPR Technology for Regenerative Medicine
核心洞察
One Genomics (搜索), co-founded by Harvard Professor George Church, has announced a strategic research collaboration with Kyoto University's CiRA Foundation (搜索) to advance precision genome engineering technologies.
The partnership combines One Genomics (搜索)' proprietary high-precision CRISPR (搜索) design platform, including its patented "Safeguard" approach, with CiRA Foundation (搜索)'s world-leading expertise in induced pluripotent stem cell manufacturing and regenerative medicine.
The collaboration aims to address critical challenges in conventional genome engineering, including off-target mutations and lack of fine-tuning capabilities that restrict precision and safety in clinical applications.
One Genomics (搜索), an AI-focused genomics company advancing de-aging (搜索) research, has entered into a strategic research collaboration with the CiRA Foundation (搜索) to develop next-generation precision genome engineering technologies. The partnership brings together One Genomics' proprietary CRISPR (搜索) design platform with CiRA Foundation's expertise in induced pluripotent stem (iPS) cell manufacturing and regenerative medicine applications.
The collaboration addresses significant limitations in current genome engineering approaches that have hindered broader clinical adoption. According to the companies, conventional CRISPR (搜索)-based technologies face critical challenges including off-target mutations, bystander effects, and a general lack of ability to fine-tune editing outcomes. These constraints restrict the precision, safety, and reliability required for advanced cellular engineering, particularly in clinically relevant human cell contexts.
Combining Complementary Technologies
Under the research agreement, One Genomics (搜索) will contribute its high-precision, fine-tunable CRISPR (搜索) design platform, including its patented "Safeguard" approach. The CiRA Foundation (搜索) will apply these technologies in human iPS cells, leveraging its world-leading expertise in regenerative medicine to improve engineering performance across relevant cellular contexts.
The CiRA Foundation (搜索), established as an offshoot of Kyoto University's Center for iPS Cell Research and Application in April 2020, operates as a public interest corporation focused on providing top-tier iPS cell technologies at affordable prices. The foundation engages in iPS manufacturing, quality control, and storage, while actively advancing research and development aimed at automating iPS cell manufacturing.
Leadership and Vision
One Genomics (搜索) was co-founded by several prominent figures in genomics and biotechnology, including George Church, Ph.D., Professor at Harvard Medical School and world-renowned geneticist and serial biotechnology entrepreneur. The founding team also includes MIT-trained AI entrepreneur Diana Luan and former Harvard research fellows Masaki Kawamata, Ph.D., and Motoshi Hayano, Ph.D.
The company is building foundational technologies for cellular reprogramming with potential applications toward systemic rejuvenation, guided by a vision of "making aging (搜索) optional." The team is developing frontier AI virtual cell and system models to simulate how human cells and biological systems age and recover function, alongside high-precision, fine-tunable genome engineering capabilities to enable programmable control of cell state.
Broader Applications Beyond Aging
The collaboration's scope extends beyond aging (搜索) research to encompass genetic and epigenetic approaches that could enable genome-guided applications including genetic disease (搜索) modeling and correction. The partnership aims to advance genome engineering technologies that provide greater precision, controllability, and reliability for both cellular and clinical applications.
The strategic alliance represents a convergence of cutting-edge AI-driven genomics research with established regenerative medicine expertise, potentially accelerating the development of more precise and safer genome editing tools for therapeutic applications.